Search results
Showing 811 to 825 of 2208 results for guidelines
This indicator covers the percentage of patients with a new diagnosis of asthma on or after (start date) with a record of an objective test between 3 months before or 3 months after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers patient experiences of maternity services. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the percentage of patients with COPD who have had influenza immunisation in the preceding 1 August to 31 March. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM106
Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome (MIB223)
NICE has developed a medtech innovation briefing (MIB) on Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome .
Targeted-release budesonide for treating primary IgA nephropathy (TA937)
Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.
This indicator covers infant Mortality. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Ambu aScope4 Broncho for use in unexpected difficult airways (HTG312)
Evidence-based recommendations on Ambu aScope4 Broncho for use in unexpected difficult airways.
Atrial fibrillation: DOACs and Vitamin K antagonists (IND247)
This indicator covers the percentage of patients with atrial fibrillation and a last recorded CHA2DS2-VASc score of 2 or more who are currently prescribed a direct-acting oral anticoagulant (DOAC) if eligible, or a vitamin K antagonist if not eligible for a DOAC or a DOAC is declined, clinically unsuitable or not indicated. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM231
HumiGard for preventing inadvertent perioperative hypothermia (HTG428)
Evidence-based recommendations on HumiGard for preventing inadvertent perioperative hypothermia.
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
This indicator covers the establishing and maintaining of a register of patients aged 18 or over with a BMI of 27.5 kg/m2 or more (or 30 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM222
This indicator covers the establishing and maintaining of a register of patients aged 18 or over with a BMI of 23 kg/m2 or more (or 25 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM221
Evidence-based recommendations on holmium laser prostatectomy. This involves using heat from a laser to break down the extra tissue in the prostate.
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.
We want you to be involved in our work - whether you’re commenting on our draft recommendations, taking part in guidance development or attending a committee meeting, your voice is important to us.